Sirolimus in Treating Patients With Advanced Pancreatic Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00499486
First received: July 10, 2007
Last updated: August 5, 2010
Last verified: August 2010

July 10, 2007
August 5, 2010
January 2005
Not Provided
  • Proportion of patients surviving after 6 months [ Designated as safety issue: No ]
  • Response rate (complete and partial response, stable and progressive disease) as assessed by RECIST [ Designated as safety issue: No ]
  • Overall and progression-free survival at 6 and 12 months [ Designated as safety issue: No ]
  • Relationship between activation of PI3K/Akt/mTOR/S6K pathway and survival [ Designated as safety issue: No ]
  • Toxicity as assessed by NCI CTCAE v3.0 [ Designated as safety issue: Yes ]
  • Proportion of patients surviving after 6 months
  • Response rate (complete and partial response, stable and progressive disease) as assessed by RECIST
  • Overall and progression-free survival at 6 and 12 months
  • Relationship between activation of PI3K/Akt/mTOR/S6K pathway and survival
  • Toxicity as assessed by NCI CTCAE v3.0
Complete list of historical versions of study NCT00499486 on ClinicalTrials.gov Archive Site
Pharmacokinetics [ Designated as safety issue: No ]
Pharmacokinetics
Not Provided
Not Provided
 
Sirolimus in Treating Patients With Advanced Pancreatic Cancer
Phase II Clinical, Biological and Pharmacological Study of Rapamycin (Rapamune®, Sirolimus) in Patients With Advanced Pancreatic Cancer

RATIONALE: Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well sirolimus works in treating patients with advanced pancreatic cancer.

OBJECTIVES:

Primary

  • To determine the proportion of patients with previously treated advanced pancreatic cancer surviving at 6 months after treatment with single agent rapamycin.
  • To evaluate the relationship between activation of the PI3/Akt/mTOR/S6K signaling pathway in tumor tissues and rapamycin activity in this patient population.
  • To characterize toxicity of rapamycin in this patient population.

Secondary

  • To determine the response rate, median time to treatment failure, and median survival of patients with previously treated advanced pancreatic cancer who are treated with single agent rapamycin.
  • To characterize the pharmacokinetics of rapamycin in this patient population.
  • To explore pharmacogenomic variables that affect rapamycin pharmacokinetics and clinical activity in this patient population.
  • To determine the pharmacodynamic effects of rapamycin on S6 kinase activation in PBMC, normal skin, and normal oral mucosa obtained from patients treated with the drug and its relationship with rapamycin pharmacokinetics and clinical effects.
  • To explore biomarkers in tumor tissues that might be associated with rapamycin clinical effects.

OUTLINE: Patients receive oral sirolimus once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients undergo blood, normal skin, and tumor tissue collection at baseline and periodically during study for pharmacological, biological, and genotyping studies. Blood samples are analyzed by LC/MS/MS assay to assess rapamycin pharmacokinetics (PKs) during courses 1 and 2 and to determine baseline CYP3A4 activity. Samples are also analyzed by genotyping studies to assess CYP3A4 polymorphisms. Pharmacodynamic activity of rapamycin is assessed in peripheral blood mononuclear cells isolated from PK blood samples using a kinase assay to measure S6K activity. Tumor tissue is collected from pretreatment tumor samples obtained at the time of diagnosis or surgery or by biopsy from patients for whom pre-study tumor specimens are not available. Patients undergo skin biopsies at baseline and on day 1 of course 2 to obtain samples of normal skin. Patients also undergo oral mucosa smears at baseline and weekly during course 1. Tumor tissue, normal skin, and oral mucosa samples are assessed by IHC staining of S6K and p-S6K and by RT-PCR for cyclin D1 and p27.

Interventional
Phase 2
Primary Purpose: Treatment
Pancreatic Cancer
  • Drug: sirolimus
  • Genetic: polymorphism analysis
  • Genetic: reverse transcriptase-polymerase chain reaction
  • Other: immunohistochemistry staining method
  • Other: laboratory biomarker analysis
  • Other: liquid chromatography
  • Other: mass spectrometry
  • Other: pharmacological study
  • Procedure: biopsy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

Inclusion criteria:

  • Histologically proven adenocarcinoma of the pancreas

    • Locally-advanced or advanced disease which has progressed after one prior gemcitabine-containing regimen
  • Unidimensionally measurable disease (defined as at least one unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan) OR evaluable disease
  • Tumor tissue available for IHC assessment OR willingness to undergo a safe biopsy of tumor tissue

Exclusion criteria:

  • Histologic or cytologic diagnosis that is not consistent with adenocarcinoma, including adenosquamous, islet cell, cystadenoma or cystadenocarcinoma, carcinoid, or small or large cell carcinoma or lymphoma
  • Adenocarcinoma arising from a site other than the pancreas (e.g., distal common bile duct, ampulla of vater or periampullary duodenum)
  • Known brain metastases

PATIENT CHARACTERISTICS:

Inclusion criteria:

  • ECOG performance status 0-1
  • WBC > 3,500 cells/mm³
  • ANC > 1,500 cells/mm³
  • Hemoglobin > 9 g/dL
  • Serum creatinine ≤ 2.0 mg/dL
  • Bilirubin ≤ 2 mg/dL
  • ALT, AST, and alkaline phosphatase ≤ 5 times upper limit of normal
  • Triglycerides and total cholesterol < 2 times upper limit of normal
  • Not pregnant or nursing

Exclusion criteria:

  • Uncontrolled medical conditions that could potentially increase the risk of toxicities or complications of this therapy, including immunodeficiency and chronic treatment with immunosuppressors
  • Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease
  • Active infections
  • History of concurrent malignancy or history of a second malignancy within the past 5 years
  • Clinically significant cardiovascular disease, including myocardial infarction (within 12 months prior to randomization), unstable angina, grade II or greater peripheral vascular disease, uncontrolled congestive heart failure, or uncontrolled hypertension (i.e., systolic blood pressure (BP) > 170 mm Hg, diastolic BP > 95 mm Hg)

PRIOR CONCURRENT THERAPY:

Exclusion criteria:

  • Any unresolved chronic toxicity greater than CTCAE grade 2 from previous anticancer therapy
  • Any previous surgery, excluding minor procedures (e.g., dental work or skin biopsy) within 4 weeks of enrollment
  • Participation in an investigational new drug trial within 1 month of starting trial
  • Treatment with chemotherapy within 30 days of day 1 treatment
  • At least 10 days since prior and no concurrent:

    • Cyclosporine
    • Diltiazem
    • Ketoconazole
    • Rifampin
    • St. Johns wort
    • Grapefruit juice
  • Concurrent phenytoin, carbamazepine, barbiturates, or phenobarbital
  • No other concurrent investigational or commercial agents
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00499486
JHOC-J0415, CDR0000549899, P30CA006973, JHOC-J0415, JHOC-04-06-16-01
Not Provided
Not Provided
Sidney Kimmel Comprehensive Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Manuel Hidalgo, MD, PhD Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center
August 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP